Mytesi Reports Net Product Revenue of $11.5M in 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy JAGX?
Reports net product revenue $11.5M vs. $11.7M last year. Mytesi prescription volume decreased approximately 3.7% in the year 2025 over 2024, by approximately 5.8% in the fourth quarter of 2025 over the third quarter of 2025, and by approximately 12.2% in the fourth quarter of 2025 over the fourth quarter of 2024. Prescription volume differs from invoiced sales volume, which reflects, among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAGX
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jaguar Health Reports Q4 2025 Earnings Highlights
- Revenue Growth: Jaguar Health reported a net revenue of approximately $3.2 million for Q4 2025, reflecting a 5% increase from Q3 2025, although it represents an 8% decline compared to Q4 2024, indicating challenges in revenue stability.
- Strategic Partnership: The transformative out-license agreement with Future Pak for Mytesi provides $18 million upfront, with $16 million already received, which will support the development of its rare disease pipeline, enhancing Crofelemer's profitability.
- Clinical Advancements: The company is in late-stage clinical development for rare disease intestinal failure, with promising data showing a reduction in parenteral support needs by up to 37%, and aims to file a new drug application by 2027, targeting a market opportunity estimated at $8 billion.
- Market Challenges: Despite the partnership with Future Pak enhancing commercialization capabilities, prescription volume for Mytesi decreased by approximately 12.2% in Q4 2025 compared to the previous year, and the company faces regulatory approval challenges for new drug applications, which may impact future revenue growth.
See More
Jaguar Health Completes Study on Chemotherapy-Induced Diarrhea in Dogs
- Study Completion: Jaguar Health announced the completion of its effectiveness study on crofelemer delayed-release tablets for chemotherapy-induced diarrhea in dogs, with results expected to be submitted in Q2 2026, potentially paving the way for full drug approval.
- FDA Approval Renewal: The FDA has granted a fifth and final renewal of conditional approval for Canalevia-CA1 until December 21, 2026, underscoring the drug's significance in treating chemotherapy-induced diarrhea and addressing the market's need for effective solutions.
- Significant Clinical Results: The use of crofelemer in dogs receiving neratinib chemotherapy resulted in a 30% reduction in both the incidence and severity of diarrhea, providing strong support for the drug's clinical application and effectiveness.
- Large Market Potential: With approximately 90 million dogs in the U.S., over 11 million of which suffer from diarrhea annually, there is a pressing demand for effective treatment options, positioning Jaguar Health's product to fill this market gap.
See More
Jaguar Health Reports Q4 2025 Financial Results
- Revenue Decline: Jaguar Health reported Q4 2025 revenue of $3.2 million, an 8.6% year-over-year decrease, indicating significant market pressure and sales challenges that could impact future liquidity and investor confidence.
- Widening Net Loss: The net loss attributable to common shareholders increased to $53.6 million in 2025 from $38.5 million in 2024, reflecting a $15.1 million rise that highlights severe challenges in cost control and profitability, potentially raising shareholder concerns about the company's future.
- Prescription Volume Drop: Mytesi prescription volume decreased by approximately 3.7% in 2025 compared to 2024, with a 5.8% decline in Q4 2025 over Q3 2025, suggesting weak market demand that may affect future revenue growth and market share.
- Minimal License Revenue: The company recognized only $42,500 in license fees from a securities purchase agreement with a European partner in Q4 2025, indicating that revenues from non-prescription Neonorm products were negligible, which may limit the company's investment capacity in new product development.
See More
Jaguar Announces Extension of MVID Clinical Trial
- Clinical Trial Extension: Napo Pharmaceuticals announced the initiation of a single-blind extension phase for its MVID trial, supported by the FDA, aiming to improve clinical outcomes by reducing parenteral support (PS) requirements, which could significantly lower co-morbidity risks associated with MVID.
- Patient Participation: Currently, approximately 30% of MVID patients have completed the double-blind treatment phase, with clinical investigators supporting their participation in the single-blind extension phase to further assess the clinical benefits of crofelemer, enhancing treatment efficacy.
- Regulatory Pathway Exploration: Jaguar anticipates that this extension phase may facilitate obtaining Breakthrough Therapy designation from the FDA, potentially providing expedited regulatory pathways for new drug approval to address the urgent treatment needs of this ultrarare disease.
- Global Clinical Network: The clinical trial has sites in the US, Italy, and the UAE, having received approvals from the FDA, EMA, and respective health ministries, demonstrating Jaguar's commitment and capability to advance MVID treatment on a global scale.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Jaguar Health Reports Q4 2025 Earnings Highlights
- Revenue Growth: Jaguar Health reported a net revenue of approximately $3.2 million for Q4 2025, reflecting a 5% increase from Q3 2025, although it represents an 8% decline compared to Q4 2024, indicating challenges in revenue stability.
- Strategic Partnership: The transformative out-license agreement with Future Pak for Mytesi provides $18 million upfront, with $16 million already received, which will support the development of its rare disease pipeline, enhancing Crofelemer's profitability.
- Clinical Advancements: The company is in late-stage clinical development for rare disease intestinal failure, with promising data showing a reduction in parenteral support needs by up to 37%, and aims to file a new drug application by 2027, targeting a market opportunity estimated at $8 billion.
- Market Challenges: Despite the partnership with Future Pak enhancing commercialization capabilities, prescription volume for Mytesi decreased by approximately 12.2% in Q4 2025 compared to the previous year, and the company faces regulatory approval challenges for new drug applications, which may impact future revenue growth.
See More
Jaguar Health Completes Study on Chemotherapy-Induced Diarrhea in Dogs
- Study Completion: Jaguar Health announced the completion of its effectiveness study on crofelemer delayed-release tablets for chemotherapy-induced diarrhea in dogs, with results expected to be submitted in Q2 2026, potentially paving the way for full drug approval.
- FDA Approval Renewal: The FDA has granted a fifth and final renewal of conditional approval for Canalevia-CA1 until December 21, 2026, underscoring the drug's significance in treating chemotherapy-induced diarrhea and addressing the market's need for effective solutions.
- Significant Clinical Results: The use of crofelemer in dogs receiving neratinib chemotherapy resulted in a 30% reduction in both the incidence and severity of diarrhea, providing strong support for the drug's clinical application and effectiveness.
- Large Market Potential: With approximately 90 million dogs in the U.S., over 11 million of which suffer from diarrhea annually, there is a pressing demand for effective treatment options, positioning Jaguar Health's product to fill this market gap.
See More
Jaguar Health Reports Q4 2025 Financial Results
- Revenue Decline: Jaguar Health reported Q4 2025 revenue of $3.2 million, an 8.6% year-over-year decrease, indicating significant market pressure and sales challenges that could impact future liquidity and investor confidence.
- Widening Net Loss: The net loss attributable to common shareholders increased to $53.6 million in 2025 from $38.5 million in 2024, reflecting a $15.1 million rise that highlights severe challenges in cost control and profitability, potentially raising shareholder concerns about the company's future.
- Prescription Volume Drop: Mytesi prescription volume decreased by approximately 3.7% in 2025 compared to 2024, with a 5.8% decline in Q4 2025 over Q3 2025, suggesting weak market demand that may affect future revenue growth and market share.
- Minimal License Revenue: The company recognized only $42,500 in license fees from a securities purchase agreement with a European partner in Q4 2025, indicating that revenues from non-prescription Neonorm products were negligible, which may limit the company's investment capacity in new product development.
See More
Jaguar Announces Extension of MVID Clinical Trial
- Clinical Trial Extension: Napo Pharmaceuticals announced the initiation of a single-blind extension phase for its MVID trial, supported by the FDA, aiming to improve clinical outcomes by reducing parenteral support (PS) requirements, which could significantly lower co-morbidity risks associated with MVID.
- Patient Participation: Currently, approximately 30% of MVID patients have completed the double-blind treatment phase, with clinical investigators supporting their participation in the single-blind extension phase to further assess the clinical benefits of crofelemer, enhancing treatment efficacy.
- Regulatory Pathway Exploration: Jaguar anticipates that this extension phase may facilitate obtaining Breakthrough Therapy designation from the FDA, potentially providing expedited regulatory pathways for new drug approval to address the urgent treatment needs of this ultrarare disease.
- Global Clinical Network: The clinical trial has sites in the US, Italy, and the UAE, having received approvals from the FDA, EMA, and respective health ministries, demonstrating Jaguar's commitment and capability to advance MVID treatment on a global scale.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
